Palatin Technologies Inc (PTN) stock
Close on Nov 12, 2026Market cap $11.70MP/E –Yield –
Palatin Technologies Inc reported revenue of $8.83M for fiscal 2026. Free cash flow was -$13.58M. At the latest close the market valued the company at $11.70M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- $11.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.75
- Dividend yield
- –
- Free cash flow yield
- -116.10%
Fundamentals
- Revenue
- $8.83M
- Net income
- -$8.38M
- EPS, diluted
- -$2.96
- Free cash flow
- -$13.58M
- Book value per share
- $1.71
- Diluted shares
- 4M
Trading
- Previous close
- $6.86
- Open
- $6.58
- Day's range
- $6.17 – $6.67
- Volume
- 13,486
- Average volume (20 days)
- 42,799
- Beta (5 years)
- 0.78
- 52-week range
- $4.51 – $31.00
- RSI (14 days)
- 48.8
- Volatility (1 year)
- 128.9%
- Relative volume
- 0.24×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTN | S&P 500 | Difference | PTN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.2% | -2.7% | −20.5 pts | ||
| 3 months | -30.6% | -1.7% | −28.9 pts | ||
| Year to date | -57.3% | +11.9% | −69.2 pts | ||
| 1 year | -40.5% | +12.0% | −52.5 pts | ||
| 3 years | -93.4% | +78.2% | −171.6 pts | -59.6% | +21.2% |
| 5 years | -98.7% | +73.2% | −171.9 pts | -58.0% | +11.6% |
| 10 years | -99.0% | +309.6% | −408.7 pts | -37.0% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Palatin Technologies filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- Update
- Update
About Palatin Technologies
Pharmaceutical Preparations
Palatin Technologies, Inc. is a biopharmaceutical company dedicated to developing targeted therapeutics that modulate the melanocortin receptor system. The company primarily focuses on developing melanocortin receptor-4 selective agonists, including long-acting peptides and oral small molecules, to treat obesity and rare neuroendocrine conditions such as hypothalamic obesity and Prader-Willi syndrome. Additionally, Palatin develops melanocortin receptor-1 agonist products aimed at treating inflammatory and autoimmune diseases, including ocular conditions like dry eye disease, as well as ulcerative colitis and diabetic nephropathy. The company operates through a single reportable segment and collaborates with pharmaceutical partners, including Boehringer Ingelheim and Altanispac Labs, to advance and commercialize its drug candidates.
Company profile, executives and historyPalatin Technologies stock: common questions
What is Palatin Technologies's stock price?
PTN closed at $6.57 on Nov 12, 2026, down 4.23% on the day. Over the past 52 weeks it traded between $4.51 and $31.00.
What is Palatin Technologies's market cap?
Palatin Technologies was worth $11.70M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PTN's P/E ratio?
Palatin Technologies lost money over fiscal 2026 (diluted EPS -$2.96), so it has no meaningful P/E ratio.
How much revenue does Palatin Technologies make?
Palatin Technologies reported revenue of $8.83M for fiscal 2026.
Does Palatin Technologies pay a dividend?
No. Palatin Technologies has not paid a cash dividend over the last twelve months.
How has PTN stock performed over the past year?
Including dividends, PTN returned -40.5% over the past year, against +12.0% for the S&P 500.
How many PTN shares are sold short?
0M shares were sold short at the latest FINRA report, 20.88% of the float, or 7.4 days of average trading volume.
Who are Palatin Technologies's competitors?
Companies most similar to Palatin Technologies by business, industry and size include BIOA, RANI, ALMS, EVMN, PRAX.
See a number that looks wrong?